Blood Test May Offer New Window Into Alzheimer’s Progression

Blood Test May Offer New Window Into Alzheimer’s Progression

A new ultrasensitive blood test has shown promise for identifying advanced tau pathology in Alzheimer’s disease (AD) and may offer a more scalable way to assess disease stage and severity.In a cross-sectional study, a plasma immunoassay for endogenously cleaved microtubule-binding region tau (eMTBR-tau) accurately identified advanced tau pathology in the brain and performed comparably to a more complex mass spectrometry method.This “scalable immunoassay could broaden research access and support clinical evaluation,” the authors wrote.The study was presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference and published online on November 16 in JAMA.Strong Tie to Tau PathologyPlasma phosphorylated tau 217 (p-tau217), a measure of soluble tau pathology, is increasingly used to identify AD-related amyloid pathology but is less specific for the insoluble tau tangles that more closely track neurodegeneration and cognitive decline.Plasma eMTBR-tau243 has emerged as a promising marker of insoluble tau tangles, but testing has relied on mass spectrometry, which is available in relatively few laboratories.In collaboration with Alamar Biosciences, Inc., Nicholas Ashton, PhD, senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute in Sun City, Arizona, developed a high-sensitivity immunoassay for plasma eMTBR-tau that requires just 35 µL of plasma compared with 1.5 mL for mass spectrometry.The assay was evaluated in a study of 521 brain donors with blood samples collected before death from two US autopsy cohorts and 207 participants from two tau PET imaging cohorts.Across both autopsy cohorts, plasma eMTBR-tau concentrations increased markedly with advancing neurofibrillary tangle pathology, particularly at Braak stages V and VI, when tau pathology has spread into the neocortex.At Braak stage VI, eMTBR-tau levels were 50.5-fold and 25.2-fold higher than at stages I-II in the two cohorts, respectively (P < .001 for both). The corresponding increases for p-tau217 were considerably smaller, at 4.6-fold and 3.2-fold.In one autopsy cohort, eMTBR-tau also performed significantly better than p-tau217 in distinguishing advanced from earlier Braak stages, with an area under the curve (AUC) of 0.93 vs 0.84 (P < .001). The difference was not statistically significant after adjustment in the second cohort.Findings from the tau-PET imaging cohorts reinforced the neuropathologic results.In the 99-participant TRIAD cohort, eMTBR-tau concentrations were nearly 60-fold higher at tau-PET Braak stages V-VI than at stage 0 compared with a 4.9-fold increase for p-tau217.In the BioFINDER-2 cohort, the immunoassay showed strong agreement with mass spectrometry measurements (correlation coefficient, 0.93 overall and 0.96 among amyloid-positive participants). Both methods also identified regional tau-PET positivity with similarly high accuracy, with AUCs ranging from 0.96 to 0.99 for the immunoassay and 0.97 to 0.99 for mass spectrometry.Ashton emphasized that it’s “late-stage tau that we’re detecting through this biomarker,” adding, “I still think we’re missing that sensitivity, or maybe missing that novel biomarker for the earlier [Braak] stage regions.”The investigators acknowledged several limitations, including the cross-sectional design, relatively small imaging cohorts, and limited racial and ethnic diversity. Many eMTBR-tau values at early Braak stages were below the assay’s lower limit of quantification.Larger prospective studies are needed to establish clinical cutoffs, determine whether the test predicts cognitive decline or treatment response, and validate its performance across laboratories.For now, the immunoassay may be most useful for expanding research into blood-based staging of AD, potentially complementing existing biomarkers such as p-tau217, the investigators noted.Ashton said the smaller blood volume required could also support decentralized research and remote blood collection, although these applications require further study.“I think scalability is the next step,” he said. “I think this immunoassay is going to help us determine a lot more about what this biomarker means in the context of Alzheimer’s disease.”A New Window of OpportunityCommenting on the findings, Tatiana Marcal, MD, senior director of medical affairs and clinical programs at the Alzheimer’s Association, said eMTBR-tau could eventually complement existing blood biomarkers rather than replace them.“P-tau217 and eMTBR-tau are likely complementary, and there may eventually be a series or panel that could measure and help with staging of someone’s underlying biology,” Marcal told Medscape Medical News.“P-tau217 helps identify Alzheimer’s pathology, while eMTBR-tau may provide additional information about tau burden and disease stage,” she said.However, more data are needed to determine how the findings might translate into clinical practice and whether they could help identify patients most likely to benefit from treatment, said Marcal.Ultimately, she said, “this progress opens a window of opportunity to go further, supporting staging and a more precise, personalized approach to Alzheimer’s and all other dementias.”The study was supported by multiple research grants and foundations. Bioventix supplied antibodies, and Alamar Biosciences performed immunoassay measurements. Ashton reported having advisory, educational, and consulting relationships with multiple companies, including Alamar Biosciences. Marcal reported having no disclosures.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.